Ignite Creation Date:
2025-12-24 @ 7:13 PM
Ignite Modification Date:
2026-01-24 @ 11:43 PM
Study NCT ID:
NCT04614103
Status:
RECRUITING
Last Update Posted:
2025-11-12
First Post:
2020-10-21
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Sponsor:
Iovance Biotherapeutics, Inc.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Metastatic Non Small Cell Lung Cancer | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | LN-145 | View |
| None | Cell Therapy | View |
| None | Autologous Adoptive Cell Therapy | View |
| None | Cellular Immuno-therapy | View |
| None | Tumor Infiltrating Lymphocytes | View |
| None | TIL | View |
| None | IL-2 | View |
| None | Non Small Cell Lung Cancer | View |
| None | NSCLC | View |
| None | Second line Lung Cancer | View |
| None | Bronchial Neoplasms | View |
| None | Carcinoma | View |
| None | Lung Disease | View |
| None | Metastatic Lung Cancer | View |
| None | Metastatic Non Small Cell Lung Cancer | View |
| None | Metastatic NSCLC | View |
| None | Lung Carcinoma | View |
| None | PD-L1 | View |
| None | Stage IV Lung Cancer | View |
| None | Stage IV Non-Small Cell Lung Cancer | View |
| None | Stage IV NSCLC | View |
| None | Systemic Therapy | View |
| None | 2nd line therapy | View |
| None | Second line therapy | View |
| None | CPI | View |
| None | Immune checkpoint inhibitor (ICI) | View |
| None | NSCLC Recurrent | View |
| None | Recurrent Lung Cancer | View |
| None | Recurrent Lung Carcinoma | View |